A trifecta of newly inked tech partnerships—from Eli Lilly, Bristol Myers Squibb and Incyte—exemplify the increasingly central role that AI is playing in drug development. Artificial intelligence is ...

Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence, announcing a sweeping agreement with Anthropic to deploy its AI tool Claude as the “shared ...

Since 1971, Travel + Leisure editors have followed one mission: to inform, inspire, and guide travelers to have deeper, more meaningful experiences. T+L's editors have traveled to countries all over ...

UPDATE: The high temperature at Cleveland Hopkins topped out at 88 degrees on Monday, meaning the city has yet to reach the 90-degree threshold so far in 2026. The high at the airport reached 89 ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. On ...

Bristol Myers Squibb has formed a broad partnership with Hengrui Pharma, paying $600 million upfront to advance 13 early-stage programs from across the two companies’ pipelines. The deal could be ...

The deal between BMS and Hengrui involves 13 assets spanning the disease areas of oncology, haematology and immunology. Credit: PixelBiss / Shutterstock.com. Bristol Myers Squibb (BMS) and Chinese ...

Of the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb. The remaining five assets will be jointly discovered. Bristol Myers Squibb ...

A fund that invests in the companies in the S&P 500 can be a great way to start a portfolio and invest for the long term. Vanguard Mid-CAP ETF offers a diversified option to invest in numerous mid-cap ...